VVOS

Vivos Therapeutics finds itself at a critical crossroads, balancing a desperate need for capital against the threat of losing its Nasdaq listing. The filing reveals a company attempting to trade equity for survival, utilizing a combination of debt-to-equity swaps and new convertible notes to bridge a widening funding gap. While these moves provide a temporary reprieve, the company's ability to survive depends entirely on its capacity to raise additional millions in equity by the end of 2026.

The Q1 2026 filing presents a stark contrast between top-line momentum and bottom-line instability. Vivos has successfully proven that its new business model can generate significant revenue and higher gross margins by owning the patient journey from diagnosis to treatment. However, the cost of this transition has been a dramatic increase in the burn rate and a reliance on high-cost debt to fund acquisitions. Investors are now faced with a binary outcome: either the SCN and AIM Detroit models can be scaled rapidly enough to reach a break-even point before cash runs out, or the company will be forced into further dilutive financing or a potential delisting from Nasdaq. The resolution of the Ortho-Tain lawsuit removes a legal cloud, but the immediate focus remains on the June 1st deadline to submit a compliance plan to Nasdaq. Ultimately, the filing reveals a company with a potentially viable product and a superior distribution strategy, but one that is currently suffocating under the weight of its own capitalization structure and operational overhead.